Cargando…

Vaccine-Elicited Tier 2 HIV-1 Neutralizing Antibodies Bind to Quaternary Epitopes Involving Glycan-Deficient Patches Proximal to the CD4 Binding Site

Eliciting broad tier 2 neutralizing antibodies (nAbs) is a major goal of HIV-1 vaccine research. Here we investigated the ability of native, membrane-expressed JR-FL Env trimers to elicit nAbs. Unusually potent nAb titers developed in 2 of 8 rabbits immunized with virus-like particles (VLPs) express...

Descripción completa

Detalles Bibliográficos
Autores principales: Crooks, Ema T., Tong, Tommy, Chakrabarti, Bimal, Narayan, Kristin, Georgiev, Ivelin S., Menis, Sergey, Huang, Xiaoxing, Kulp, Daniel, Osawa, Keiko, Muranaka, Janelle, Stewart-Jones, Guillaume, Destefano, Joanne, O’Dell, Sijy, LaBranche, Celia, Robinson, James E., Montefiori, David C., McKee, Krisha, Du, Sean X., Doria-Rose, Nicole, Kwong, Peter D., Mascola, John R., Zhu, Ping, Schief, William R., Wyatt, Richard T., Whalen, Robert G., Binley, James M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4449185/
https://www.ncbi.nlm.nih.gov/pubmed/26023780
http://dx.doi.org/10.1371/journal.ppat.1004932
_version_ 1782373823382814720
author Crooks, Ema T.
Tong, Tommy
Chakrabarti, Bimal
Narayan, Kristin
Georgiev, Ivelin S.
Menis, Sergey
Huang, Xiaoxing
Kulp, Daniel
Osawa, Keiko
Muranaka, Janelle
Stewart-Jones, Guillaume
Destefano, Joanne
O’Dell, Sijy
LaBranche, Celia
Robinson, James E.
Montefiori, David C.
McKee, Krisha
Du, Sean X.
Doria-Rose, Nicole
Kwong, Peter D.
Mascola, John R.
Zhu, Ping
Schief, William R.
Wyatt, Richard T.
Whalen, Robert G.
Binley, James M.
author_facet Crooks, Ema T.
Tong, Tommy
Chakrabarti, Bimal
Narayan, Kristin
Georgiev, Ivelin S.
Menis, Sergey
Huang, Xiaoxing
Kulp, Daniel
Osawa, Keiko
Muranaka, Janelle
Stewart-Jones, Guillaume
Destefano, Joanne
O’Dell, Sijy
LaBranche, Celia
Robinson, James E.
Montefiori, David C.
McKee, Krisha
Du, Sean X.
Doria-Rose, Nicole
Kwong, Peter D.
Mascola, John R.
Zhu, Ping
Schief, William R.
Wyatt, Richard T.
Whalen, Robert G.
Binley, James M.
author_sort Crooks, Ema T.
collection PubMed
description Eliciting broad tier 2 neutralizing antibodies (nAbs) is a major goal of HIV-1 vaccine research. Here we investigated the ability of native, membrane-expressed JR-FL Env trimers to elicit nAbs. Unusually potent nAb titers developed in 2 of 8 rabbits immunized with virus-like particles (VLPs) expressing trimers (trimer VLP sera) and in 1 of 20 rabbits immunized with DNA expressing native Env trimer, followed by a protein boost (DNA trimer sera). All 3 sera neutralized via quaternary epitopes and exploited natural gaps in the glycan defenses of the second conserved region of JR-FL gp120. Specifically, trimer VLP sera took advantage of the unusual absence of a glycan at residue 197 (present in 98.7% of Envs). Intriguingly, removing the N197 glycan (with no loss of tier 2 phenotype) rendered 50% or 16.7% (n = 18) of clade B tier 2 isolates sensitive to the two trimer VLP sera, showing broad neutralization via the surface masked by the N197 glycan. Neutralizing sera targeted epitopes that overlap with the CD4 binding site, consistent with the role of the N197 glycan in a putative “glycan fence” that limits access to this region. A bioinformatics analysis suggested shared features of one of the trimer VLP sera and monoclonal antibody PG9, consistent with its trimer-dependency. The neutralizing DNA trimer serum took advantage of the absence of a glycan at residue 230, also proximal to the CD4 binding site and suggesting an epitope similar to that of monoclonal antibody 8ANC195, albeit lacking tier 2 breadth. Taken together, our data show for the first time that strain-specific holes in the glycan fence can allow the development of tier 2 neutralizing antibodies to native spikes. Moreover, cross-neutralization can occur in the absence of protecting glycan. Overall, our observations provide new insights that may inform the future development of a neutralizing antibody vaccine.
format Online
Article
Text
id pubmed-4449185
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-44491852015-06-09 Vaccine-Elicited Tier 2 HIV-1 Neutralizing Antibodies Bind to Quaternary Epitopes Involving Glycan-Deficient Patches Proximal to the CD4 Binding Site Crooks, Ema T. Tong, Tommy Chakrabarti, Bimal Narayan, Kristin Georgiev, Ivelin S. Menis, Sergey Huang, Xiaoxing Kulp, Daniel Osawa, Keiko Muranaka, Janelle Stewart-Jones, Guillaume Destefano, Joanne O’Dell, Sijy LaBranche, Celia Robinson, James E. Montefiori, David C. McKee, Krisha Du, Sean X. Doria-Rose, Nicole Kwong, Peter D. Mascola, John R. Zhu, Ping Schief, William R. Wyatt, Richard T. Whalen, Robert G. Binley, James M. PLoS Pathog Research Article Eliciting broad tier 2 neutralizing antibodies (nAbs) is a major goal of HIV-1 vaccine research. Here we investigated the ability of native, membrane-expressed JR-FL Env trimers to elicit nAbs. Unusually potent nAb titers developed in 2 of 8 rabbits immunized with virus-like particles (VLPs) expressing trimers (trimer VLP sera) and in 1 of 20 rabbits immunized with DNA expressing native Env trimer, followed by a protein boost (DNA trimer sera). All 3 sera neutralized via quaternary epitopes and exploited natural gaps in the glycan defenses of the second conserved region of JR-FL gp120. Specifically, trimer VLP sera took advantage of the unusual absence of a glycan at residue 197 (present in 98.7% of Envs). Intriguingly, removing the N197 glycan (with no loss of tier 2 phenotype) rendered 50% or 16.7% (n = 18) of clade B tier 2 isolates sensitive to the two trimer VLP sera, showing broad neutralization via the surface masked by the N197 glycan. Neutralizing sera targeted epitopes that overlap with the CD4 binding site, consistent with the role of the N197 glycan in a putative “glycan fence” that limits access to this region. A bioinformatics analysis suggested shared features of one of the trimer VLP sera and monoclonal antibody PG9, consistent with its trimer-dependency. The neutralizing DNA trimer serum took advantage of the absence of a glycan at residue 230, also proximal to the CD4 binding site and suggesting an epitope similar to that of monoclonal antibody 8ANC195, albeit lacking tier 2 breadth. Taken together, our data show for the first time that strain-specific holes in the glycan fence can allow the development of tier 2 neutralizing antibodies to native spikes. Moreover, cross-neutralization can occur in the absence of protecting glycan. Overall, our observations provide new insights that may inform the future development of a neutralizing antibody vaccine. Public Library of Science 2015-05-29 /pmc/articles/PMC4449185/ /pubmed/26023780 http://dx.doi.org/10.1371/journal.ppat.1004932 Text en https://creativecommons.org/publicdomain/zero/1.0/ This is an open-access article distributed under the terms of the Creative Commons Public Domain declaration, which stipulates that, once placed in the public domain, this work may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose.
spellingShingle Research Article
Crooks, Ema T.
Tong, Tommy
Chakrabarti, Bimal
Narayan, Kristin
Georgiev, Ivelin S.
Menis, Sergey
Huang, Xiaoxing
Kulp, Daniel
Osawa, Keiko
Muranaka, Janelle
Stewart-Jones, Guillaume
Destefano, Joanne
O’Dell, Sijy
LaBranche, Celia
Robinson, James E.
Montefiori, David C.
McKee, Krisha
Du, Sean X.
Doria-Rose, Nicole
Kwong, Peter D.
Mascola, John R.
Zhu, Ping
Schief, William R.
Wyatt, Richard T.
Whalen, Robert G.
Binley, James M.
Vaccine-Elicited Tier 2 HIV-1 Neutralizing Antibodies Bind to Quaternary Epitopes Involving Glycan-Deficient Patches Proximal to the CD4 Binding Site
title Vaccine-Elicited Tier 2 HIV-1 Neutralizing Antibodies Bind to Quaternary Epitopes Involving Glycan-Deficient Patches Proximal to the CD4 Binding Site
title_full Vaccine-Elicited Tier 2 HIV-1 Neutralizing Antibodies Bind to Quaternary Epitopes Involving Glycan-Deficient Patches Proximal to the CD4 Binding Site
title_fullStr Vaccine-Elicited Tier 2 HIV-1 Neutralizing Antibodies Bind to Quaternary Epitopes Involving Glycan-Deficient Patches Proximal to the CD4 Binding Site
title_full_unstemmed Vaccine-Elicited Tier 2 HIV-1 Neutralizing Antibodies Bind to Quaternary Epitopes Involving Glycan-Deficient Patches Proximal to the CD4 Binding Site
title_short Vaccine-Elicited Tier 2 HIV-1 Neutralizing Antibodies Bind to Quaternary Epitopes Involving Glycan-Deficient Patches Proximal to the CD4 Binding Site
title_sort vaccine-elicited tier 2 hiv-1 neutralizing antibodies bind to quaternary epitopes involving glycan-deficient patches proximal to the cd4 binding site
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4449185/
https://www.ncbi.nlm.nih.gov/pubmed/26023780
http://dx.doi.org/10.1371/journal.ppat.1004932
work_keys_str_mv AT crooksemat vaccineelicitedtier2hiv1neutralizingantibodiesbindtoquaternaryepitopesinvolvingglycandeficientpatchesproximaltothecd4bindingsite
AT tongtommy vaccineelicitedtier2hiv1neutralizingantibodiesbindtoquaternaryepitopesinvolvingglycandeficientpatchesproximaltothecd4bindingsite
AT chakrabartibimal vaccineelicitedtier2hiv1neutralizingantibodiesbindtoquaternaryepitopesinvolvingglycandeficientpatchesproximaltothecd4bindingsite
AT narayankristin vaccineelicitedtier2hiv1neutralizingantibodiesbindtoquaternaryepitopesinvolvingglycandeficientpatchesproximaltothecd4bindingsite
AT georgievivelins vaccineelicitedtier2hiv1neutralizingantibodiesbindtoquaternaryepitopesinvolvingglycandeficientpatchesproximaltothecd4bindingsite
AT menissergey vaccineelicitedtier2hiv1neutralizingantibodiesbindtoquaternaryepitopesinvolvingglycandeficientpatchesproximaltothecd4bindingsite
AT huangxiaoxing vaccineelicitedtier2hiv1neutralizingantibodiesbindtoquaternaryepitopesinvolvingglycandeficientpatchesproximaltothecd4bindingsite
AT kulpdaniel vaccineelicitedtier2hiv1neutralizingantibodiesbindtoquaternaryepitopesinvolvingglycandeficientpatchesproximaltothecd4bindingsite
AT osawakeiko vaccineelicitedtier2hiv1neutralizingantibodiesbindtoquaternaryepitopesinvolvingglycandeficientpatchesproximaltothecd4bindingsite
AT muranakajanelle vaccineelicitedtier2hiv1neutralizingantibodiesbindtoquaternaryepitopesinvolvingglycandeficientpatchesproximaltothecd4bindingsite
AT stewartjonesguillaume vaccineelicitedtier2hiv1neutralizingantibodiesbindtoquaternaryepitopesinvolvingglycandeficientpatchesproximaltothecd4bindingsite
AT destefanojoanne vaccineelicitedtier2hiv1neutralizingantibodiesbindtoquaternaryepitopesinvolvingglycandeficientpatchesproximaltothecd4bindingsite
AT odellsijy vaccineelicitedtier2hiv1neutralizingantibodiesbindtoquaternaryepitopesinvolvingglycandeficientpatchesproximaltothecd4bindingsite
AT labranchecelia vaccineelicitedtier2hiv1neutralizingantibodiesbindtoquaternaryepitopesinvolvingglycandeficientpatchesproximaltothecd4bindingsite
AT robinsonjamese vaccineelicitedtier2hiv1neutralizingantibodiesbindtoquaternaryepitopesinvolvingglycandeficientpatchesproximaltothecd4bindingsite
AT montefioridavidc vaccineelicitedtier2hiv1neutralizingantibodiesbindtoquaternaryepitopesinvolvingglycandeficientpatchesproximaltothecd4bindingsite
AT mckeekrisha vaccineelicitedtier2hiv1neutralizingantibodiesbindtoquaternaryepitopesinvolvingglycandeficientpatchesproximaltothecd4bindingsite
AT duseanx vaccineelicitedtier2hiv1neutralizingantibodiesbindtoquaternaryepitopesinvolvingglycandeficientpatchesproximaltothecd4bindingsite
AT doriarosenicole vaccineelicitedtier2hiv1neutralizingantibodiesbindtoquaternaryepitopesinvolvingglycandeficientpatchesproximaltothecd4bindingsite
AT kwongpeterd vaccineelicitedtier2hiv1neutralizingantibodiesbindtoquaternaryepitopesinvolvingglycandeficientpatchesproximaltothecd4bindingsite
AT mascolajohnr vaccineelicitedtier2hiv1neutralizingantibodiesbindtoquaternaryepitopesinvolvingglycandeficientpatchesproximaltothecd4bindingsite
AT zhuping vaccineelicitedtier2hiv1neutralizingantibodiesbindtoquaternaryepitopesinvolvingglycandeficientpatchesproximaltothecd4bindingsite
AT schiefwilliamr vaccineelicitedtier2hiv1neutralizingantibodiesbindtoquaternaryepitopesinvolvingglycandeficientpatchesproximaltothecd4bindingsite
AT wyattrichardt vaccineelicitedtier2hiv1neutralizingantibodiesbindtoquaternaryepitopesinvolvingglycandeficientpatchesproximaltothecd4bindingsite
AT whalenrobertg vaccineelicitedtier2hiv1neutralizingantibodiesbindtoquaternaryepitopesinvolvingglycandeficientpatchesproximaltothecd4bindingsite
AT binleyjamesm vaccineelicitedtier2hiv1neutralizingantibodiesbindtoquaternaryepitopesinvolvingglycandeficientpatchesproximaltothecd4bindingsite